NEOTRAC shortened treatment duration without improving pCR in HER2-positive inoperable breast cancer
Concurrent neoadjuvant radiotherapy shortened treatment duration but did not improve pathological complete response or survival.
Concurrent neoadjuvant radiotherapy shortened treatment duration but did not improve pathological complete response or survival.
A single-arm phase 1/2 trial reported a 39.1% pathologic complete response rate among resected patients, with grade 4 toxicities in 10%.
Adjunctive hydrogen gas inhalation was associated with numerically fewer moderate toxicities and exploratory serum metabolomic changes during head and neck chemoradiotherapy.
Simultaneous integrated boost radiotherapy was associated with 96% two-year disease-free survival versus 70% with sequential boost in anal cancer.
Three-year locoregional recurrence-free survival was 90.8%, with most locoregional recurrences occurring within or near the radiation field.
A nodal-to-primary tumor volume ratio of at least 15% was associated with lower three-year distant metastasis-free survival after extended-field radiotherapy.
Weekly cisplatin remained non-inferior to three-weekly cisplatin at five years in postoperative high-risk head and neck chemoradiotherapy.
Induction chemotherapy showed no overall survival benefit, with outcomes differing by disease risk and the intensity of pre-radiotherapy treatment.
Longer pembrolizumab exposure after chemoradiation was associated with lower mortality, but immortal time bias prevents causal interpretation.
Concurrent chemotherapy improved progression-free survival without a significant overall survival benefit in early primary tumors with low-volume nodal disease.
Patients reported persistently worse quality of life and functioning approximately two years after chemoradiotherapy than matched individuals without cancer.